Navigation Links
Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
Date:6/10/2008

MONTVALE, N.J., June 10 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by TAP Pharmaceuticals Inc. in connection with its Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets (lansoprazole), 15mg and 30mg.

Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Prevacid SoluTab product with the U.S. Food & Drug Administration (FDA) in November 2007. Following receipt of the notice from the FDA that Barr's ANDA had been accepted for filing, Barr notified the New Drug Application (NDA) and patent holder.

On June 9, 2008, Ethypharm, S.A., Takeda Pharmaceutical Co., Ltd. and TAP Pharmaceuticals Inc. filed suits in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Prevacid SoluTab (lansoprazole) had annual sales of approximately $428 million in the U.S., based on IMS sales data for the 12-month period ending March 2008.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
2. Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules
3. Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd.
4. Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
5. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
6. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
7. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
8. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
9. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
10. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
11. Icahn Confirms Intention to Nominate Three Directors at Biogen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
(Date:5/17/2013)... 2013  Insero Health, Inc., a company developing natural ... related neurological disorders, is today reporting top-line results from ... in patients with drug-resistant epilepsy.  The data are being ... Xll meeting by Dr. Steven Schachter ... Scientific Advisory Board.  In this study, INS001 appeared safe ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... a surge in demand for nanotech tools in the ... by a New York consulting firm that focuses on ... also projected that sales of nanotech tools could double ... nanotechnology focuses on remarkable applications ranging from computer displays ...
... Hiring talent is a serious business. Many companies maintain ... matching the right person with the right skills to ... dollars are routinely spent on all manner of testing ... thinking styles, psychologies and talents of potential hires. Countless ...
... ago, while attending a conference on equity capital, the ... more than a few snickers from the participants. ... along with the entrepreneur's personal funds is nothing to ... Entrepreneurship Monitor (GEM) report. , ,William D. Bygrave, ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Hiring in the name of talent 2Hiring in the name of talent 3Hiring in the name of talent 4Family reunion? Don't forget your business plan 2Family reunion? Don't forget your business plan 3
(Date:5/17/2013)... Societies for Experimental Biology (FASEB) released a new ... trends highlighting the devastating impact of sequestration on the ... follows a May 15th Senate Appropriations Committee hearing featuring ... the $1.6 billion cut the agency sustained in FY ... on the scientific community." , According to data ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society for Developmental Biology (SDB) 72nd Annual Meeting ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the SDB 2013 Annual Meeting. , Awards are ...
(Date:5/16/2013)... CAMBRIDGE, MA -- Injectable nanoparticles developed at MIT ... Type 1 diabetes to constantly monitor their blood-sugar ... nanoparticles were designed to sense glucose levels in ... amount of insulin, thereby replacing the function of ... with Type 1 diabetes. Ultimately, this type of ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... a common herbicide might be causing die-offs in stream ... long-term study raise concerns over the role of atrazine ... that while impacts of the herbicide, atrazine, may not ... of the chemical may be deadly to amphibians in ...
... Scientists from the NIOZ Royal Netherlands Institute for Sea ... record for tropical central Africa over the past 25,000 ... colleague from the University of Bremen, The scientists developed ... land temperatures based on the molecular fossils of soil ...
... the hardest tissue produced by the body. It cannot regenerate ... that is lost by the time the tooth appears in ... vulnerable to wear, damage, and decay. For this reason, it ... or even whole teeth, using culturing and transplantation techniques. In ...
Cached Biology News:Salamanders suffer delayed effects of common herbicide 2Salamanders suffer delayed effects of common herbicide 3Microfossils unravel climate history of tropical Africa 2Scientists re-grow dental enamel from cultured cells 2
... Hormone Receptor 2 ( Abpromise ... Antigen: Synthetic peptide: AFRHCNPNGTWDFMHSLN, ... of Human Parathyroid Hormone Receptor 2 ... 5746 Swiss ...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
Biology Products: